Nalaganje...

AKR1C3 as a Target in Castrate Resistant Prostate Cancer

Aberrant androgen receptor (AR) activation is the major driver of castrate resistant prostate cancer (CRPC). CRPC is ultimately fatal and more therapeutic agents are needed to treat this disease. Compounds that target the androgen axis by inhibiting androgen biosynthesis and or AR signaling are pote...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Adeniji, Adegoke O., Chen, Mo, Penning, Trevor M.
Format: Artigo
Jezik:Inglês
Izdano: 2013
Teme:
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3805777/
https://ncbi.nlm.nih.gov/pubmed/23748150
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jsbmb.2013.05.012
Oznake: Označite
Brez oznak, prvi označite!